Rheumatoid Arthritis Disease Progression Modeling (Q57425123)

2

0 references

Bradley Ferguson

3

0 references

Michael O’Kelly

4

0 references

Seth Berry

5

0 references

Wei Xiao

Longitudinal model-based meta-analysis in rheumatoid arthritis: an application toward model-based drug development

6

0 references

publication date

5 September 2013

0 references

published in

Drug Information Journal

0 references

volume

47

0 references

issue

6

0 references

page(s)

641-650

0 references

cites work

1 reference

https://api.crossref.org/works/10.1177%2F2168479013499571

Comparison of rheumatoid arthritis clinical trial outcome measures: a simulation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2168479013499571

Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2168479013499571

Nonlinear mixed effects models for repeated measures data

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2168479013499571

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2168479013499571

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2168479013499571

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2168479013499571

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2168479013499571

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2168479013499571

Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2168479013499571

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2168479013499571

Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2168479013499571

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2168479013499571

Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2168479013499571

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2168479013499571